Michael F. MacLean serves as the Chief Financial and Chief Business Officer at Avidity Biosciences, Inc., a biotechnology company focused on developing RNA therapeutics. In his role, MacLean is responsible for overseeing the financial operations and strategic business development of the company, playing a crucial role in guiding Avidity's growth and success in the competitive biotech industry. His leadership has been instrumental in securing funding and forging key partnerships that have propelled Avidity's innovative research and development efforts forward. Prior to joining Avidity Biosciences, MacLean held several high-level positions in the biotechnology and pharmaceutical sectors. He has a proven track record of driving financial performance and strategic growth, having served as the Chief Financial Officer at Mirati Therapeutics, where he helped lead the company through significant milestones, including its initial public offering. MacLean's extensive experience also includes roles at Amylin Pharmaceuticals and Eli Lilly and Company, where he honed his skills in corporate finance, business development, and strategic planning. His background in these areas has been vital in his current position at Avidity, where he continues to leverage his expertise to advance the company's mission of delivering transformative therapies to patients. MacLean's achievements in the biotech industry are marked by his ability to navigate complex financial landscapes and foster collaborative relationships that drive innovation. At Avidity, he has been pivotal in securing significant investments and partnerships that have supported the company's clinical programs and expanded its research capabilities. His strategic vision and financial acumen have not only strengthened Avidity's position in the market but also contributed to the broader advancement of RNA-based therapeutics. MacLean's dedication to excellence and his commitment to improving patient outcomes through cutting-edge science make him a valuable asset to Avidity Biosciences and the biotechnology community at large.